Chimeric antigen receptor-engineered T-cell therapy for liver cancer

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor-engineered T-cell (CAR-T) therapy is a novel immunotherapy with success in hematological malignancies.
• Its application is being explored for solid tumors, including liver cancer, due to unmet clinical needs.

Purpose of the Study:

• To review the immune characteristics of liver cancer.
• To discuss obstacles and progress in applying CAR-T therapy to liver cancer.
• To explore strategies for overcoming challenges and managing side effects.

Main Methods:

• Literature search of PubMed and Web of Science databases (prior to December 2017) using keywords related to CAR-T and liver cancer.
• Manual search of references from primary articles.
• Inclusion of data from ClinicalTrials.gov for clinical trial information.

Main Results:

• The liver's tolerogenic nature and immunosuppressive tumor microenvironment pose significant challenges for CAR-T efficacy.
• Obstacles include lack of specific antigens, limited CAR-T cell trafficking, and penetration into tumors.
• Preclinical studies demonstrate potent antitumor activity, with ongoing research into targets like Glypican-3 and Mucin-1.

Conclusions:

• CAR-T therapy for liver cancer is in early stages of exploration, requiring further research.
• Despite challenges, CAR-T therapy holds potential as a future treatment for liver cancers.
• Optimism exists for CAR-T therapy to provide a new therapeutic avenue for liver cancer patients.